Scarica l'app Stockscreener
0.97
15.43%
0.1297
Precedente Chiudi:
$0.8403
Aprire:
$0.86
Volume 24 ore:
4.53M
Relative Volume:
2.69
Capitalizzazione di mercato:
$68.98M
Reddito:
$391.70K
Utile/perdita netta:
$-52.34M
Rapporto P/E:
-1.2933
EPS:
-0.75
Flusso di cassa netto:
$-45.92M
1 W Prestazione:
+88.39%
1M Prestazione:
+163.59%
6M Prestazione:
+50.67%
1 anno Prestazione:
-14.16%
Intervallo 1D:
$0.8106
$1.02
Intervallo di 1 settimana:
$0.5194
$1.02
Portata 52W:
$0.2425
$1.47
Ovid Therapeutics Inc Stock (OVID) Company Profile
Nome
Ovid Therapeutics Inc
Settore
Industria
Telefono
212-776-4381
Indirizzo
441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY
Confronta OVID con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OVID
Ovid Therapeutics Inc
|
0.97 | 59.75M | 391.70K | -52.34M | -45.92M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-08 | Ripresa | B. Riley Securities | Buy |
| 2024-06-18 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-04-30 | Iniziato | B. Riley Securities | Buy |
| 2024-04-29 | Iniziato | H.C. Wainwright | Buy |
| 2024-04-05 | Iniziato | Wedbush | Outperform |
| 2023-12-21 | Iniziato | BTIG Research | Buy |
| 2023-10-13 | Iniziato | Oppenheimer | Outperform |
| 2021-04-20 | Downgrade | Cantor Fitzgerald | Buy → Neutral |
| 2021-03-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-12-02 | Downgrade | Citigroup | Buy → Neutral |
| 2020-12-02 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-04 | Iniziato | RBC Capital Mkts | Outperform |
| 2018-04-20 | Iniziato | Ladenburg Thalmann | Buy |
Mostra tutto
Ovid Therapeutics Inc Borsa (OVID) Ultime notizie
Analyzing Ovid Therapeutics Inc. with risk reward ratio charts2025 Winners & Losers & Safe Swing Trade Setup Alerts - Newser
How high can Ovid Therapeutics Inc. stock go2025 Momentum Check & Risk Adjusted Swing Trade Ideas - Newser
Ovid Therapeutics (NASDAQ:OVID) Rating Increased to Hold at Wall Street Zen - Defense World
Has Ovid Therapeutics Inc. formed a bullish divergenceJuly 2025 Rallies & Safe Capital Allocation Plans - Newser
Ovid Therapeutics Transfers Stock to Nasdaq Capital Market - MSN
What makes Ovid Therapeutics Inc. stock price move sharplyJobs Report & Verified Chart Pattern Signals - Newser
Ovid Therapeutics (OVID) up more than 100% since Aug 4 - AInvest
Analyzing Ovid Therapeutics Inc. with multi timeframe chartsAnalyst Upgrade & Community Verified Watchlist Alerts - Newser
Ovid Therapeutics Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Tools to monitor Ovid Therapeutics Inc. recovery probabilityDividend Hike & Smart Money Movement Alerts - Newser
Ovid Therapeutics Plunges 11.42% on Q2 Loss, Pipeline Progress - AInvest
B.Riley Financial Initiates Ovid Therapeutics(OVID.US) With Buy Rating, Announces Target Price $3 - 富途牛牛
Ovid Therapeutics shares fall 6.76% premarket after reporting business updates and second quarter results. - AInvest
Ovid Therapeutics Reports Increased Revenue Amid Challenges - TipRanks
Ovid Therapeutics Q2 Earnings: Revenue Up, Net Loss Widens - AInvest
Ovid Therapeutics shares rise 34.92% intraday after reporting business updates and a $7.0 million royalty monetization agreement. - AInvest
Ovid Therapeutics Reports Q2 2025 Results: $38.3M Cash, $6.3M Revenue, Net Loss of $4.7M - AInvest
Ovid Therapeutics Surges 36.76%: What's Fueling the Biotech Breakout? - AInvest
Ovid Therapeutics earnings beat by $0.10, revenue topped estimates - Investing.com Canada
Ovid Therapeutics: Navigating the Maze of Rare Disease Innovation and Financial Constraints - AInvest
Ovid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Ovid Therapeutics Reports Q2 2025 Financials, $7mln Royalty Deal, Q3 2025 Results Expected - AInvest
Ovid Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results | OVID Stock News - GuruFocus
Ovid Therapeutics Reports Business Updates and Second Quarter 20 - GuruFocus
Ovid Therapeutics Inc. SEC 10-Q Report - TradingView
Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results - GlobeNewswire
Ovid's Next-Gen Epilepsy Drug Nears Key Data as Company Strengthens Cash Position with $7M Deal - Stock Titan
Lucid Capital Markets initiates Ovid Therapeutics stock with Buy rating By Investing.com - Investing.com Canada
Lucid Capital Markets initiates Ovid Therapeutics stock with Buy rating - Investing.com
Ovid Therapeutics (NASDAQ:OVID) Given Consensus Rating of “Buy” by Brokerages - Defense World
How to track smart money flows in Ovid Therapeutics Inc.Exit Point & Weekly Watchlist for Hot Stocks - Newser
Will Ovid Therapeutics Inc. price bounce be sustainableSwing Entry Insight With Forecast Accuracy - Newser
Ovid Therapeutics (NASDAQ:OVID) Trading Up 7.9% – Here’s Why - Defense World
Is Ovid Therapeutics Inc. stock poised for growthFree Watchlist for Low Risk High Return - Newser
Ovid Therapeutics (OVID) to Release Quarterly Earnings on Tuesday - Defense World
Ovid Therapeutics OVID 2025Q2 Earnings Preview Upside Potential on Strategic Partnerships - AInvest
Ovid Therapeutics Maintains Buy Rating with $3.00 Price Target from B.Riley Financial Analyst Madison Elsaadi. - AInvest
B.Riley assumes coverage on Ovid Therapeutics stock with Buy rating - Investing.com Australia
Short interest data insights for Ovid Therapeutics Inc.Earnings Impact and Stock Reaction Analysis - Newser
Ovid Therapeutics Inc. Stock Analysis and ForecastMarket-crushing profits - Jammu Links News
What are analysts’ price targets for Ovid Therapeutics Inc. in the next 12 monthsUnlock powerful trading signals and alerts - Jammu Links News
Is it the right time to buy Ovid Therapeutics Inc. stockOutstanding capital growth - Jammu Links News
Does Ovid Therapeutics Inc. stock perform well during market downturnsAchieve rapid wealth accumulation with smart picks - Jammu Links News
Is Ovid Therapeutics Inc. stock overvalued or undervaluedTremendous financial leverage - jammulinksnews.com
Should I hold or sell Ovid Therapeutics Inc. stock in 2025Invest smarter with actionable stock recommendations - Jammu Links News
What institutional investors are buying Ovid Therapeutics Inc. stockBuild a balanced portfolio for long-term success - Jammu Links News
How strong is Ovid Therapeutics Inc. company’s balance sheetMaximize gains with strategic stock entries - Jammu Links News
How does Ovid Therapeutics Inc. compare to its industry peersFree Wealth Planning Blueprint - Jammu Links News
Why is Ovid Therapeutics Inc. stock attracting strong analyst attentionSuperior stock growth - Jammu Links News
What is the dividend policy of Ovid Therapeutics Inc. stockUnrivaled growth potential - Jammu Links News
Ovid Therapeutics Inc Azioni (OVID) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.41%
0.88%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):